Argus analyst David Toung raised the firm’s price target on Stryker (SYK) to $450 from $410 and keeps a Buy rating on the shares. Argus expects a smooth transition as Preston Wells has been named to succeed Glenn Boehnlein as chief financial officer, the analyst tells investors in a research note. In addition, the firm sees the Inari Medical acquisition and Spinal Implants divestiture as positives for Stryker’s growth profile and return on investment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker price target raised to $413 from $409 at Truist
- Alphatec likely to benefit as Stryker exits spinal implants, says Lake Street
- Stryker Corp’s Strong Earnings Call Highlights Growth and Strategy
- Stryker price target raised to $427 from $384 at Goldman Sachs
- Stryker price target raised to $402 from $380 at Deutsche Bank
Questions or Comments about the article? Write to editor@tipranks.com